Please login to the form below

Not currently logged in
Email:
Password:

GSK buys 13 generic products from BMS

GlaxoSmithKline has acquired the branded generics business of Bristol-Myers Squibb in five countries for £14.2m

GlaxoSmithKline(GSK) has acquired the branded generics business of Bristol-Myers Squibb (BMS) in five countries for £14.2m.

The deal strengthens GSK's strategy to accelerate growth in emerging markets and will see the pharmaceutical giant take over a portfolio of 13 branded pharmaceuticals in Lebanon, Jordan, Syria, Libya and Yemen.

In 2008, GSK purchased several mature branded products in Pakistan and Egypt, including a manufacturing plant in Giza, from BMS. Under the terms of this latest agreement, BMS will continue to supply the acquired products until the anticipated transfer of manufacture to GSK's Giza plant in 2011.

GSK has been actively building its portfolio within emerging markets for some time – Gaining exclusive access to Dr. Reddy's portfolio and future pipeline of more than 100 branded pharmaceuticals, entering into a joint venture with Shenzhen Neptunus for flu vaccines in China, acquiring a stake in Africa's biggest generic drug maker, Aspen and GSK acquiring UCB SA's marketed product portfolio for £483m gaining several pharmaceutical brands including Keppra for the treatment of epilepsy and Xytal and Zyrtec for allergic rhinitis are just a few recent examples.

2nd July 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Dovetail

We're award-winning joint working specialists. We help our clients to transform healthcare through effective collaboration, and deliver work to feel...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics